Welcome to our dedicated page for Addus Homecare SEC filings (Ticker: ADUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Addus HomeCare Corporation filings document a home care provider with personal care, hospice and home health operations. Form 8-K reports furnish quarterly and annual results of operations, Regulation FD disclosures and exhibit press releases, while amended 8-K filings provide acquisition-related financial statements and pro forma information for the completed purchase of Gentiva's personal care business by Addus HealthCare, a wholly owned subsidiary.
Proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation votes and related governance disclosures. The filing record also includes capital-structure, material-event and shareholder-vote disclosures for the company's common stock.
Addus HomeCare Corp director Esteban Lopez sold shares in an open-market transaction. On May 21, 2026, he sold 250 shares of Addus HomeCare common stock at a price of $93.00 per share. Following this sale, he directly owns 3,200 shares of the company’s common stock.
Addus HomeCare Corp director Esteban Lopez reported an open-market sale of Common Stock. On May 19, 2026, he sold 250 shares at $93.00 per share. After this transaction, Lopez directly holds 3,450 shares of Addus HomeCare common stock.
Addus HomeCare Corporation reported solid growth for the quarter ended March 31, 2026. Net service revenues rose to $363.6 million from $337.7 million, driven mainly by higher personal care volumes and hospice census.
Net income increased to $25.1 million from $21.2 million, with diluted EPS of $1.36 versus $1.16. Personal care revenue grew 8.8% to $281.1 million, hospice 7.1% to $65.8 million, while home health declined 7.0% to $16.7 million as volumes fell but margins improved.
The company generated $52.4 million of operating cash flow, ended the quarter with $103.1 million in cash, and reduced revolver borrowings to $94.3 million. It also received $6.2 million of ARPA funding, with $14.6 million remaining deferred. After quarter-end, Addus acquired HomeCourt Home Care in Indiana for about $12.5 million, expanding its personal care footprint.
Addus HomeCare reported solid first-quarter 2026 growth and expanded its footprint. Net service revenues were $363.6 million, up 7.7% from 2025, while net income rose to $25.1 million and diluted EPS increased to $1.36 from $1.16. Adjusted EBITDA grew 9.7% to $44.5 million, and adjusted diluted EPS reached $1.62, up from $1.42.
Personal care, at $281.1 million, drove results with 6.5% organic revenue growth, supported by higher volumes and Texas and Illinois rate increases. Hospice revenue was $65.8 million with 7.7% organic growth, while home health revenue of $16.7 million declined modestly.
The company acquired the personal care operations of HomeCourt Home Care in Indiana, serving about 240 clients with approximately $9.7 million in annualized revenue, and signed a definitive agreement for a similarly sized Indiana business. As of March 31, 2026, Addus held $103.1 million in cash and $94.3 million in bank debt, generated $52.4 million in operating cash flow, and had $547.8 million of revolver availability.
Addus HomeCare Corporation is asking shareholders to vote at its 2026 virtual annual meeting on electing two Class II directors, ratifying PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026, and approving on an advisory basis its named executive officer compensation.
The June 10, 2026 meeting will be held by live audio webcast only, with April 23, 2026 as the record date and 18,664,776 common shares entitled to vote. The proxy details board structure, committee responsibilities, ESG priorities and a pay program that ties both annual bonuses and equity awards to Adjusted EBITDA performance.
Addus HomeCare Corp executive Cliff Donald Blessing reported a small open-market sale of company stock. As EVP and Chief Development Officer, he sold 178 shares of common stock at $93.61 per share. After this transaction, he directly holds 12,183 shares of Addus HomeCare common stock.
The company states this sale was executed under a previously established Rule 10b5-1 trading plan and was made to cover tax obligations arising from the vesting of restricted stock awards. This indicates the transaction was pre-planned and primarily driven by tax-related needs rather than discretionary trading.
Addus HomeCare Corp ownership filing: The Vanguard Group amended its Schedule 13G to report 0 shares of Common Stock and 0% beneficial ownership. The amendment explains an internal realignment on January 12, 2026 that disaggregated certain Vanguard subsidiaries and business divisions for separate reporting.
Addus HomeCare Corporation filed Amendment No. 1 to its annual report for the year ended December 31, 2025. The amendment primarily refreshes the cover page information and updates the exhibit list.
The company is incorporating by reference its Insider Trading Policy as Exhibit 19.1 and its Compensation Recoupment Policy as Exhibit 97.1, which were omitted from the original filing. The amendment also restates Item 15 to reference previously filed consolidated financial statements and includes updated CEO and CFO certification exhibits.
The amendment states that no consolidated financial statements are included and that, except for these changes, it does not modify other disclosures in the original annual report. As of March 11, 2026, the company had 18,643,615 shares of common stock outstanding.
Addus HomeCare Corp executive Monica Raines reported an open-market sale of 224 shares of common stock. The transaction occurred at a price of $102.15 per share and was reported as a sale in the open market or a private transaction. After this trade, her directly held stake stood at 13,577 shares of Addus HomeCare common stock.
According to the footnotes, this sale was executed under a previously established Rule 10b5-1 trading plan, adopted on 03-13-2025, and was made to satisfy tax obligations arising from the vesting of restricted stock awards granted by the company.